CLINICAL TRIALS OPERATIONS
Release Date: May 11, 1999
RFP AVAILABLE: N01DA-9-8095
P.T.
National Institute on Drug Abuse
The National Institute on Drug Abuse (NIDA) is soliciting proposals from
qualified organizations having the capability to conduct Phase I and II
clinical trials of potential treatment drugs, both new and marketed, for the
treatment of drug addiction. Specifically, treatment drugs for two classes of
drugs of abuse (stimulants and opiates) will be investigated clinically under
the current Food and Drug Administration regulations and Good Clinical
Practice guidelines. The Contractor shall provide all the necessary services
to conduct clinical trials. The offeror must be highly experienced in
conducting clinical pharmacology, Phase I and II clinical trials in any
therapeutic area. Due to the nature of the study compounds which will be
evaluated under the contract, it is mandatory that offerors possess a Drug
Enforcement Administration (DEA) Research Registration for Schedules II to V
in order to handle substances under the Controlled Substances Act of 1970.
NIDA anticipates a multiple award of four five-year task order type contracts
as a result of this solicitation. RFP No. N01DA-9-8095 will be available
electronically on or about May 19, 1999 and may be accessed through the NIDA
website at URL: http://www.nida.nih.gov/RFP/RFPList.html. Responses to the
RFP will be due approximately 45 calendar days thereafter. Please note that
the RFP for this acquisition will be issued in a streamlined format which will
include only the Work Statement, Deliverables and Reporting Requirements,
Special Requirements and Mandatory Qualifications, Technical Evaluation
Criteria, and other necessary Proposal Preparation Instructions. All
information required for the submission of a proposal will be contained in or
accessible through the streamlined RFP package. Any responsible offeror may
submit a proposal which will be considered by the Government. This
advertisement does not commit the Government to award a contract.
INQUIRIES
Point of Contact:
Kenneth E. Goodling, Contracting Officer
National Institute on Drug Abuse, NIH
Contracts Management Branch, OPRM
6001 Executive Blvd., Room 3105, MSC 9543
Bethesda, Maryland 20892-9543
Electronic Mail Address: kg25d@nih.gov
Telephone: (301) 443-6677
Fax: (301) 443-7595